PATENT CLAIM ANALYSIS

Application Number: 16240617
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "454000"]

Abstract:
A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In certain embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol, cannabidiol and, optionally, terpenes such as linalool.

Claim (Index 12):
A method for reducing severity from an epileptic seizure, the method comprising:\n providing a composition that includes one or more terpenes, CBD and between 5% and 10% of delta-9-tetrahydrocannabinol by volume; and intranasally administering approximately 0.1 ml of the composition to a human subject while the human subject is actively convulsing from a seizure, the human subject incapable of administering the composition while actively convulsing.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 99.0
- Lexical Diversity: 1.4
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15710204', '14634880', '15646342', '15449535', '15449402']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6334031882485951
- 35 USC 102 Novelty (BERT): 0.5448256880738734
- Combined Prediction Score: 0.624545438231123
- Mean Citation Score: 199.099578
- Max Citation Score: 373.3064
- Similarity Product: 360.1270758993149

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test